Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Week's Exclusive Content Wall Street Loves FIGS. So Why Do Price Targets Predict a Pullback?Reported by Jennifer Woods. Article Posted: 3/2/2026. After a stunning plunge following its 2021 IPO, medical and lifestyle apparel company FIGS, Inc. (NYSE: FIGS) has rallied to a price it hasn't seen in nearly four years. The stock has surged almost 260% over the past year, including a 58% jump in the last month alone. The rally has been driven by stronger earnings and a wave of bullish analyst commentary. Yet the consensus 12-month price target sits at just $12.25 — nearly 30% below the current stock price. That gap raises a central question: how much of this recovery is supported by fundamentals, and how much is pure momentum? A closer look at FIGS' recent results and price action offers some clues. Early investors enjoyed a quick windfall after the company's IPO debuted in May 2021 at $22 per share and surged to $50 within a month as pandemic-driven demand for medical apparel spiked. As COVID-19 demand eased, the stock reversed sharply and within a year traded below $8. In the years that followed FIGS largely traded in the single digits. After dipping below $4 in April 2025, however, the stock began another pronounced rally. Earnings Momentum Sparks Rally Following steady gains after positive Q1 and Q2 2025 earnings, the Q3 2025 results, released on Nov. 6, accelerated the move higher. The report showed stronger-than-expected revenue growth, healthy demand across core categories and resilient margins despite tariff pressures. FIGS raised its full-year guidance for net revenue and adjusted EBITDA margins, and the upbeat outlook helped push the stock more than 30% higher over the following week. Zacks Research upgraded the shares to Strong Buy from Hold. Currently, $2 TRILLION worth of transactions go through the traditional network every single day. But soon, it will be funneled through the new network that the Federal Reserve has built, operates and can see in real time.
That's the part buried in the Federal Reserve Docket No. OP-1670.
In fact, on page 84 of the 93-page document, they admit that it will make it easier to track the spending of Americans. That's why I've put together 4 steps to "Fed proof" your savings Key Points - FIGS stock is up nearly 260% over the last year
- Strong earnings have fueled the rally
- Stock is trading almost 30% above the average price target
- Special Report: [Sponsorship-Ad-6-Format3]
The momentum continued after the Q4 2025 earnings report on Feb. 26. FIGS reported a 33% jump in quarterly revenue — its best quarter ever — with sales topping $200 million. Management highlighted growth in the active customer base, higher average order values and strength across its core scrubwear business, which accounts for more than three-quarters of net revenue and grew 35%. International sales rose 55%. The fourth quarter capped a solid year: full-year net revenue was up 14% year-over-year to a record $630 million, and adjusted EBITDA margin exceeded the company's target by more than 200 basis points despite tariff headwinds. Earnings And Outlook Spark Analyst Support FIGS issued an upbeat outlook, expecting continued demand partly driven by growth in healthcare jobs. The company plans to expand in new international markets, pursue growth opportunities across its businesses and continue its stock buyback program. For fiscal 2026, FIGS projects net revenue growth of 10% to 12%, with improving profitability targets. Analysts were quick to respond. Barclays raised its rating to Strong Buy from Hold, KeyCorp moved to Overweight from Sector Weight with a $17 price target, and Goldman Sachs shifted to Hold from Strong Sell. BTIG reiterated its Buy rating with a $15 target, and Telsey Advisory raised its target to $15 from $9. FIGS Stock Pushes Past Price Targets Strong earnings have been the clear catalyst for FIGS' move to four-year highs. The shares began climbing before the Q4 report, rising nearly 14% in the session ahead of the release. After the results, the rally accelerated: the stock jumped 24% on the first trading day following the report and added roughly another 10% the next day. As of March 4, the stock was trading above $17, almost 30% higher than the $12.25 average 12-month price target based on 10 analyst reports. That level is well above Morgan Stanley's $8 target from January and matches the highest target of $17 set by KeyCorp. The gap between bullish analyst commentary and relatively modest price targets suggests analysts appreciate FIGS' improving fundamentals but remain cautious about the stock's valuation. At current prices, shares trade at a price-to-earnings ratio near 90, implying much of the company's expected growth may already be priced in. Investors are clearly applauding the turnaround, but skepticism remains about whether the stock can extend its rally or if a pullback is likely.
| 
